A GAMMA-SECRETASE INHIBITOR DECREASES AMYLOID-BETA PRODUCTION IN THE CENTRAL

γ-分泌酶抑制剂可减少中央区β-淀粉样蛋白的产生

• 批准号: 8361396
• 负责人: RANDALL J BATEMAN
• 金额: $ 0.4万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8361396
• 关键词: Abeta clearance; Alzheimer' s Disease; Amyloid beta-Protein; Event; Funding; Grant; Human; Mass Spectrum Analysis; Methods; National Center for Research Resources; Neuraxis; Pathogenesis; Pharmaceutical Preparations; Principal Investigator; Production; Research; Research Infrastructure; Resources; Source; United States National Institutes of Health; abeta accumulation; biomedical resource; cost; gamma secretase; inhibitor/antagonist

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. OBJECTIVE: Accumulation of amyloid-beta (Abeta) by overproduction or underclearance in the central nervous system (CNS) is hypothesized to be a necessary event in the pathogenesis of Alzheimer's disease. However, previously, there has not been a method to determine drug effects on Abeta production or clearance in the human CNS. The objective of this study was to determine the effects of a gamma-secretase inhibitor on the production of Abeta in the human CNS.

该子项目是利用资源的众多研究子项目之一 由 NIH/NCRR 资助的中心拨款提供。子项目的主要支持 并且子项目的主要研究者可能是由其他来源提供的， 包括其他 NIH 来源。 子项目可能列出的总成本 代表子项目使用的中心基础设施的估计数量， NCRR 赠款不直接向子项目或子项目工作人员提供资金。 目的：推测中枢神经系统（CNS）中因过量产生或清除不足而导致的β-淀粉样蛋白（Abeta）积累是阿尔茨海默病发病机制中的一个必要事件。然而，此前还没有一种方法可以确定药物对人类 CNS 中 Abeta 产生或清除的影响。本研究的目的是确定 γ-分泌酶抑制剂对人类中枢神经系统中 Abeta 产生的影响。